InsideArbitrage Event Driven Monitor – June 30, 2026
Note: You can click on any section title to jump straight to the related tool or page. Merger Arbitrage TBPH: The acquisition of Theravance Biopharma, Inc. (TBPH) by Zymeworks…
Written byAsif SuriaSource: InsideArbitrage
Note: You can click on any section title to jump straight to the related tool or page. Merger Arbitrage TBPH: The acquisition of Theravance Biopharma, Inc. (TBPH) by Zymeworks Inc. (ZYME) for a closing value of $929 million. Theravance Biopharma shareholders will receive $17 in cash, representing a 3.57% discount to the stock’s last close.